Healthcare giant Johnson & Johnson has agreed to pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its discontinued, talc-based baby powder caused ovarian cancer.
The deal, announced on Monday, reported by Reuters aims to draw a line under a bitter, decade-long legal battle that has severely weighed on the pharmaceutical firm.
The proposed agreement covers about 76,000 claims in total—accounting for roughly 99.7 percent of the remaining ovarian cancer lawsuits filed across federal and state courts in the United States. Under the terms of the deal, payout funds will begin flowing in 2027, provided that at least 95 percent of eligible claimants formally agree to accept the terms.
The lawsuits stem from allegations that women developed ovarian cancer after using J&J’s talc-based baby powder for personal hygiene, with plaintiffs alleging the talc was contaminated with cancer-causing asbestos.
J&J has consistently denied the allegations, insisting that decades of independent scientific testing prove its talc was safe, asbestos-free, and non-carcinogenic. However, under pressure from mounting litigation and falling demand, the firm phased out its talc-based baby powder in North America in 2020 before stopping global sales entirely in 2023 in favour of a cornstarch-based alternative.
The agreement follows years of fiercely contested courtroom battles, high-stakes trials, and three separate failed attempts by J&J subsidiaries to resolve the liabilities through corporate bankruptcy filings.
Despite agreeing to the multi-billion-dollar payout, Johnson & Johnson maintained its long-standing stance that the legal claims lacked scientific backing, framing the settlement as a necessary commercial decision to eliminate ongoing court expenses and uncertainty.
Erik Haas, Vice President of Litigation at Johnson & Johnson, highlighted the company’s desire to focus on its primary medical business.
“While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas said in an official statement.
Lead attorneys representing the sickened women and their families welcomed the agreement, emphasizing that the resolution brings long-overdue financial relief after years of judicial delays.
Chris Seeger, one of the primary lead attorneys representing thousands of plaintiffs, hailed the deal as a fair outcome after a grueling court fight.
“We got a fair settlement, and our clients are going to be happy with it,” Seeger said in an interview, noting that total payouts could eventually rise above $7 billion depending on final claimant participation.
“More than a decade of protracted litigation and three failed bankruptcies has left tens of thousands of women and their families waiting far too long for relief,” Seeger added in a joint statement.
Christopher Tisi, a member of the Plaintiffs’ Executive Committee leading the federal litigation, echoed the sentiment regarding the tragic toll on families:
“We have watched countless clients suffer grievously… I am proud to say that this settlement will provide resolution to the lawsuits. Nothing can restore the health or the lives of those who have died from asbestos cancers.”
A Partial Legal End
The proposed deal deals exclusively with existing US claims, leaving the door open for potential future litigation while ensuring that existing plaintiffs are paid out significantly faster—within an estimated 18 months—rather than enduring another decade of appeals.
While the $5.5 billion offer marks one of the largest product liability settlements in corporate history, J&J’s legal troubles surrounding talc are not entirely over. The company continues to face individual claims elsewhere internationally, including a high-profile collective action lawsuit currently underway in the UK.
Discover more from Pluboard
Subscribe to get the latest posts sent to your email.